Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Migraine

In brief

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Key facts

Study ID
NCT03836040
Run by
Amgen
People needed
457
Starts
2019-07-19
Expected to finish
2026-11-19
Last updated by the study team
2026-07-16

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.